Manelimab (anti-PD-L1) is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1). Purity>95% (SDS-PAGE&SEC) Endotoxin Level < 0.01EU/μg
Product Properties
Isotype
Human IgG1
Light Chain Type
lambda
SDS-PAGE
26.8 kDa (Light Chain) & 50.8 kDa (Heavy Chain), under reducing conditions; 196.5 kDa, under non-reducing conditions.
Purification Method
Protein A purified
Form
Liquid
Concentration
Lot by Lot
Storage Temp
Store at -80°C,Avoid repeated freezing and thawing
Shipped In
Ice chest + Ice pads
Stability And Storage
Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS
2168561-26-8
Images
Manelimab (anti-PD-L1) (Ab182878) - Flow Cytometry Flow Cytometry analysis of unstimulated (left) or 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated (right) Jurkat cells labelling PD-L1 (red) with Manelimab (anti-PD-L1) (Ab182878) at 0.1 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Manelimab (anti-PD-L1) (Ab182878) - ELISA Immobilized Recombinant Human PD-L1 protein (rp169666) at 1.0 μg/mL can bind Manelimab (anti-PD-L1) (Ab182878) with the EC50 of 51.00 ng/mL.
Manelimab (anti-PD-L1) (Ab182878) - SEC The purity of Manelimab (anti-PD-L1) (Ab182878) is more than 95% verified by HPLC.
Associated Targets
CD274Tclin Programmed cell death 1 ligand 1 0 Activities
ZJ24F0708328